Loading chart data...
Tempus AI is exploding higher today, fueled by strong positive momentum following the release of an analysis highlighting the company's accelerating data business and its first-ever GAAP profit. Investors are also reacting to the newly finalized exclusive distribution agreement with TempraMed in Panama, which signals a significant expansion of the company's commercial footprint into international clinics and pharmacies. This move is occurring alongside a broader surge in the healthcare sector, where peers like MRNA, MRVI, and BNTX are also seeing massive gains, suggesting a strong rotation into medical and biotech information services today.
That explains the day. Whether TEM is a business worth owning is a longer question. Koyfin has the ten-year financials, margin history and valuation to answer it — 20% off for WhyTheMove readers.
No significant catalyst events detected.
TEM moved for a reason you can read above. What the company earns, owns and guides to is a separate record. Koyfin is where the question moves from today's move to the business behind it — analyst estimates, filings and earnings transcripts.
Research TEM in Koyfin →7-day full-access trial · 20% off paid plans